| Literature DB >> 33050747 |
Zhisong Wang1, Juan Wang1, Donglai Cao1, Leng Han1.
Abstract
OBJECTIVE: We aimed to explore the relationship between neutrophil-to-lymphocyte ratio (NLR) at three timepoints and prognosis of patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) undergoing elective percutaneous coronary intervention (PCI) within 1 year of PCI.Entities:
Keywords: Neutrophil-to-lymphocyte ratio; left ventricular ejection fraction; major cardiovascular event; major cerebrovascular adverse event; non-ST-elevation acute coronary syndrome; percutaneous coronary intervention; risk factor
Mesh:
Substances:
Year: 2020 PMID: 33050747 PMCID: PMC7570302 DOI: 10.1177/0300060520959510
Source DB: PubMed Journal: J Int Med Res ISSN: 0300-0605 Impact factor: 1.671
Figure 1.Patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) who underwent elective percutaneous coronary intervention within 1 year were divided into major cardiovascular and cerebrovascular adverse events (MACE) and non-MACE groups. Preoperative and postoperative (within 24 hours and after 24 hours) neutrophil-to-lymphocyte ratios (NLR) were assessed and correlated with presence of MACE.
Comparison of clinical data between MACE and non-MACE groups.
| Parameter | Total (n = 214) | MACE group (n = 32) | Non-MACE group (n = 182) | |
|---|---|---|---|---|
| Age (year) | 66.16 ± 8.16 | 70.78 ± 8.00 | 65.48 ± 8.11 | 0.001 |
| Male (%) | 148 (9.2) | 26 (81.3) | 122 (67.0) | 0.108 |
| BMI (kg/m2) | 25.85 ± 6.90 | 27.05 ± 6.44 | 25.64 ± 6.97 | 0.291 |
| Smoking (%) | 47 (22.0) | 11 (34.4) | 36 (19.8) | 0.066 |
| Hypertension (%) | 160 (74.5) | 26 (81.3) | 134 (73.6) | 0.360 |
| Diabetes (%) | 74 (34.6) | 8 (25) | 66 (36.3) | 0.217 |
| LVEF (%) | 62.82 ± 7.18 | 59.06 ± 6.11 | 63.48 ± 7.17 | 0.003 |
| LAD (mm) | 37.65 ± 5.02 | 39.44 ± 5.75 | 37.34 ± 4.84 | 0.058 |
| Drugs (%) | ||||
| Clopidogrel | 57 (26.6) | 7 (21.9) | 50 (27.5) | 0.434 |
| Ticagrelor | 155 (72.4) | 25 (78.1) | 130 (72.5) | 0.434 |
| ACEI/ARB | 93 (43.5) | 15 (46.9) | 78 (42.9) | 0.672 |
| β Blocker | 125 (58.4) | 19 (59.4) | 106 (58.2) | 0.905 |
| Blood parameters | ||||
| Preoperative neutrophil count (×109) | 4.18 ± 1.51 | 4.83 ± 1.90 | 4.07 ± 1.41 | 0.036 |
| Preoperative lymphocyte count (×109) | 1.60 ± 0.65 | 1.28 ± 0.41 | 1.65 ± 0.66 | <0.001 |
| Preoperative NLR | 3.01 ± 1.61 | 4.23 ± 2.36 | 2.79 ± 1.34 | 0.002 |
| Postoperative (within 24 h) neutrophil count (×109) | 5.31 ± 1.70 | 5.89 ± 2.40 | 5.21 ± 1.23 | 0.001 |
| Postoperative (within 24 h) lymphocyte count (×109) | 1.33 ± 0.53 | 1.03 ± 0.29 | 1.38 ± 0.54 | <0.001 |
| Postoperative (within 24 h) NLR | 4.61 ± 2.53 | 5.97 ± 3.03 | 4.37 ± 2.36 | 0.001 |
| Postoperative (after 24 h) neutrophil count (×109) | 3.96 ± 1.38 | 4.17 ± 0.81 | 3.93 ± 1.46 | 0.178 |
| Postoperative (after 24 h) lymphocyte count (×109) | 1.42 ± 0.49 | 1.26 ± 0.53 | 1.44 ± 0.48 | 0.045 |
| Postoperative (after 24 h) NLR | 3.14 ± 1.64 | 3.72 ± 1.14 | 3.03 ± 1.70 | 0.028 |
| LDL-C (mmol/L) | 2.30 ± 0.68 | 2.34 ± 0.70 | 2.29 ± 0.68 | 0.683 |
| Preoperative creatinine (μmol/L) | 72.64 ± 16.75 | 71.59 ± 17.86 | 72.82 ± 16.59 | 0.703 |
| CK-MB (ng/mL) | 8.70 ± 11.2 | 10.28 ± 10.49 | 8.42 ± 11.33 | 0.386 |
| TnI (ng/mL) | 1.03 ± 1.84 | 1.43 ± 2.00 | 0.96 ± 1.81 | 0.222 |
| Coronary artery lesions and stents | ||||
| Three-vessel lesion ratio (%) | 37 (17.3) | 12 (37.5) | 25 (13.7) | 0.001 |
| Bifurcation lesions ratio (%) | 109 (50.9) | 19 (59.4) | 90 (49.5) | 0.300 |
| Left main lesion (%) | 69 (32.2) | 7 (21.9) | 62 (34.1) | 0.174 |
| Number of stents implanted (individual) | 2.25 ± 2.10 | 1.84 ± 0.92 | 2.32 ± 2.24 | 0.239 |
| Average internal diameter of stent (mm) | 2.98 ± 0.50 | 2.92 ± 0.37 | 2.99 ± 0.52 | 0.431 |
| Total length of stent (mm) | 55.07 ± 33.92 | 48.81 ± 27.09 | 56.18 ± 34.93 | 0.258 |
| Complete revascularization (%) | 167 (78.0) | 27 (84.4) | 140 (76.9) | 0.586 |
MACE, major adverse cardiovascular and cerebrovascular event; BMI, body mass index; LVEF, left ventricular ejection fraction; LAD, left atrial diameter; ACEI, angiotensin-converting-enzyme inhibitors; ARB, angiotensin II receptor blockers; NLR, neutrophil-to-lymphocyte ratio; LDL-C, low-density lipoprotein cholesterol; CK-MB, creatine kinase; MB form; TnI, troponin.
Multivariate logistic regression analysis of major adverse cardiovascular and cerebrovascular events after percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome.
| Parameter | Odds ratio | 95% CI | |
|---|---|---|---|
| Preoperative NLR | 1.307 | 1.034–1.651 | 0.025 |
| NLR within 24 hours after operation | 1.189 | 1.014–1.394 | 0.033 |
| NLR 24 hours after operation | 1.062 | 0.806–1.400 | 0.667 |
| Age | 1.069 | 1.010–1.131 | 0.021 |
| LVEF | 0.934 | 0.884–0.987 | 0.015 |
| Three-vessel lesions | 2.508 | 0.884–0.987 | 0.060 |
NLR, neutrophil-to-lymphocyte ratio; LVEF, left ventricular ejection fraction.
Figure 2.Receiver-operator characteristic (ROC) curve of major cardiovascular and cerebrovascular adverse events predicted by preoperative neutrophil-to-lymphocyte ratio (NLR).
Figure 3.Receiver-operator characteristic (ROC) curve of major cardiovascular and cerebrovascular adverse events predicted by neutrophil-to-lymphocyte ratio (NLR) within 24 hours after surgery.